Back

Comparison between ticagrelor and clopidogrel in high bleeding risk patients with acute coronary syndrome

27 August 2022 (11:37 - 12:00)
Organised by:
Congress Presentation Part of: The role of bleeding in determining antithrombotic treatment in acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Jonathan Tjerkaski

Karolinska Institute, Stockholm (Sweden)

1 More presentation in this session

Presentation thumbnail
State-of-the-art lecture in the role of bleeding in determining DAPT .
Professor M. Valgimigli (Lugano, CH)
Slides Video

Access the full session

Session thumbnail
The role of bleeding in determining antithrombotic treatment in acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2022

27 August 2022 11:37 CET
You may be interested in
thumbnail
Congress Presentation
Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention and using direct oral anticoagulants
thumbnail
Congress Presentation
A meta-analysis on the efficacy of ticagrelor monotherapy after 3 months of dual antiplatelet therapy vs ticagrelor plus aspirin dual therapy on patients with ACS who underwent PCI
thumbnail
Congress Presentation
Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources